ArticlePolymer science & technology (Washington, D.C.)2025
Enhanced Hydrophilicity and Antifouling Performance of PEG with Sulfoxide-Containing Side Chains for Nanomedicine Applications.
Article in Polymer science & technology (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Sprayable lipid-based lubricated hydrogel coating for alleviating catheter-related mucosal damage and pain.Bioactive materials · 2026Article
- Tuning protein corona on nucleic acid nanodrugs for targeted delivery.Acta pharmaceutica Sinica. B · 2026Review
- Adhesion Mechanisms of Amyloid-Like Oligomer Monolayers Enabling Stable Surface Modification for Inert Polymers.JACS Au · 2026Article
- Advanced biosensing strategies for high-risk foodborne pathogens: a comprehensive review ofFood chemistry. Molecular sciences · 2026Review
- Advancements in RNA-based therapies from bench to bedside.npj drug discovery · 2026Review
- Nanotechnology-Driven Cancer Therapies for Precision Oncology: Advances and Clinical Outlook.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poly-(ethylene) glycol (PEG) has been widely used as an antifouling coating material for nanomedicines to improve their stability and safety. However, a growing number of studies have indicated that PEG is immunogenic and can cause unwanted immune responses, highlighting the need to develop alternative antifouling polymers for applications in nanomedicine. In this study, we report an innovative polymer, poly-(2-(methylsulfinyl)-ethyl glycidyl ether) (PMSOEGE), composed of a PEG backbone structure with sulfoxide-containing side chains. We demonstrated that PMSOEGE is highly biocompatible and more hydrophilic than conventional PEG due to the presence of highly polar and hydrophilic sulfoxide structures. Furthermore, PMSOEGE exhibits a much lower association with anti-PEG antibodies, as confirmed by an in vitro competitive enzyme-linked immunosorbent assay (ELISA). We applied PMSOEGE as a coating material for iron oxide nanoparticles (IONPs) and demonstrated that the PMSOEGE-coated IONPs showed significantly lower cellular uptake by macrophages compared with PEGylated IONPs. Protein corona analysis indicated that fewer proteins were associated with IONP@PMSOEGE. The results highlight the superior antifouling properties of PMSOEGE and highlight its potential to serve as a PEG alternative for various biological applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.